Michel Orsinger has reaffirmed his commitment to Nobel Biocare through his intention to stand for election to the Board at the company’s annual general meeting on 29 March 2012. However, due to other upcoming professional commitments, Michel Orsinger has decided, if he is elected to Nobel Biocare’s Board, to focus on various specific areas where he can add value, including leading the company’s Innovation and Technology Committee, rather than on heading the Board. Pending a successful re-election to the Board by the shareholders, the Board intends to appoint the current Chairman ad interim, Rolf Watter, as Chairman of the Board of Nobel Biocare.
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.